Patients with relapsing-remitting multiple sclerosis who used glatiramer acetate (Copaxone) for up to 26 years show sustained efficacy and safety of treatment, researchers reported here. "These were patients in the 'compassionate use' program for this drug before any multiple sclerosis drugs were approved," said investigator Rivka Riven Kreitman, MD, Vice-president for Research and Development, Teva Pharmaceutical Industries Netanya, Israel...."These patients have been very stable on Copaxone [GA] for the long term, and have had very few relapses," he explained. "We saw very few safety issues and very good efficacy." MORE